section name header

Pronunciation ⬇

tye-roe-FYE-ban

Classifications ⬆ ⬇

Therapeutic Classification: antiplatelet agents

Pharmacologic Classification: glycoprotein iib iiia inhibitors

Indications ⬆ ⬇

High Alert

Action ⬆ ⬇

  • Decreases platelet aggregation by reversibly antagonizing the binding of fibrinogen to the glycoprotein IIb/IIIa binding site on platelet surfaces.
Therapeutic effects:
  • Inhibition of platelet aggregation resulting in decreased incidence of new MI, death, or refractory ischemia with the need for repeat cardiac procedures.

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: Excreted mostly unchanged by the kidneys (65%); 25% excreted unchanged in feces.

Half-Life: 2 hr.

Time/Action Profile ⬆ ⬇

(effects on platelet function)

ROUTEONSETPEAKDURATION
IVrapid30 min‡brief‡

‡>90% inhibition of platelet aggregation at end of initial 30-min infusion.

‡Inhibition is reversible following cessation of infusion.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Noted for patients receiving heparin and aspirin in addition to tirofiban

CV: bradycardia, coronary dissection, edema, vasovagal reaction

Derm: hives, rash, sweating

GI: nausea

Hemat: bleeding, thrombocytopenia

MS: leg pain

Neuro: headache, dizziness

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), fever, pelvic pain

Interactions ⬆ ⬇

Drug-drug:

Drug-Natural Products:

Route/Dosage ⬆ ⬇

Renal Impairment

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

IV Administration:

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Aggrastat

Code ⬆

NDC Code